[Amend claim 3 as follows:]

[--]3. (twice amended) The cell composition according to claim 1, containing T lymphocytes in a ratio of about 10 to 60% expressed with respect to the total number of cells[--]

Amend claim 4 as follows:

[--]4. (twice amended) The cell composition according to claim 2, wherein the progenitor cells contain from about 0.1% to about 20% of $CD34^+$ stem cells, expressed with respect to the total number of progenitor cells[--]

[Amend claim 5 as follows:]

[--]5. (amended) The cell composition according to claim 4, wherein the progenitor cells are generated from and optionally included in peripheral blood mononuclear cells, and are selected from the group consisting of myelo-erythroïd progenitor cells, myeloïd progenitor cells, lymphoïd progenitor cells and mixtures thereof[--]

[Amend claim 6 as follows:]

[--]6. (twice amended) The cell composition according to claim 2, wherein the macrophages, myeloïd cells and the lymphocytes if present, are included in/or generated from blood mononuclear cells.[--]

Amend claim 7 as follows:

[--]7. (amended) A process for the preparation of a cell composition containing macrophages, myeloïd cells and progenitor cells, with said progenitor cells being present in an

amount of about 0.1% to about 20%, with said macrophages being in an amount of about 10 to about 60%, these percentages being expressed with respect to the total number of cells, comprising the step of mobilizing the progenitor cells in the blood of a patient by premedication of said patient with G-CSF and/or GM-CSF, or G-CSF and cyclophophosphamide, thus increasing the amount of progenitor cells in peripheral blood.[--]

[Amend claim 8 as follows:]

[--8. (amended) The process according to claim 7, further comprising coculturing the blood mononuclear cells and progenitors, after washing off the platelets, the granulocytes and erythrocytes, for about 4 to about 10 days, in a medium allowing differentiation of monocytes into macrophages and myeloïd progenitors into polynuclear cells.[--]

[Amend claim 9 as follows:]

[--9. (amended) The process according to claim 8, wherein the coculture is carried out in the presence of cytokines or growth factors selected from the group consisting of IL-3, IL-6 stem cell factor, EPO, thrombopotein, GM-CSF, G-CSF, FLAT-3 ligand, C-Kit ligand and their agonists.[--]

[Amend claim 10 as follows:]

[--10. (twice amended) The process according to claim 8, further comprising a step of activating macrophages, at the end of the coculture, by addition of γ-interferon or muramyl peptides.[--]

[Amend claim 11 as follows:]

[--]11. (twice amended) The process according to claim 7, further comprising a step of concentrating the cells obtained at the end of the coculture, and resuspension in a vehicle suitable for administration to a patient.[--]

[Amend claim 12 as follows:]

[--]12. (amended) The process according to claim 11, further comprising, after the resuspension of the coculture, a step of freezing part or the totality of the resuspension.[--]

[Amend claim 13 as follows:]

[--]13. (twice amended) Cell composition as obtained by the process according to claim 7.[--]

[Amend claim 14 as follows:]

[--]14. (twice amended) The pharmaceutical composition containing, as active substance, the cell composition according to claim 1[--]

[Amend claim 15 as follows:]

[--]15. (twice amended) Cell composition according to claim 1, wherein said composition is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells,
- from about 0.1 to about 20% of stem cells.[--]

Amend claim 17 as follows:

[--]17. (amended) The cell composition according to claim 2, containing T lymphocytes, in a ratio of about 10 to 60% expressed with respect to the total number of cells.[--]

Amend claim 18 as follows:

[--]18. (amended) The pharmaceutical composition containing, as active substance, the cell composition according to claim 2.[--]

[Amend claim 19 as follows:]

[--]19. (amended) The cell composition according to claim 2, wherein said composition is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells,
- from about 0.1 to about 20% of stem cells.[--]

REMARKS

Responsive to the preliminary determination of lack of unity set forth in the outstanding Official Action, applicants hereby provisionally elect Group II, claims 2, 4, 5, 6 and 17-19 drawn to cell and pharmaceutical compositions containing macrophages, myeloïd cells and progenitor cells, with traverse. The grounds for traverse are as follows.